摘要
目的观察普伐他汀对急性冠状动脉综合征(ACS)患者血清基质金属蛋白酶-9(MMP-9)及组织抑制因子-1(TIMP-1)水平的影响。方法选择ACS患者30例,稳定性心绞痛(SAP)患者30例,正常健康体检者28例,采用ELISA法测定其血清可溶性TIMP-1及MMP-9浓度,经普伐他汀治疗后复查TIMP-1及MMP-9的变化。结果ACS组血清MMP-9显著高于SAP组及对照组(均P<0·05),而TIMP-1显著低于SAP组及对照组(均P<0·05),SAP组MMP-9显著高于对照组(P<0·05),SAP组TIMP-1与对照组之间无差异(P>0·05);普伐他汀治疗4周后ACS患者血清MMP-9水平下降,TIMP-1水平上升,与治疗前比较差异有统计学意义(P<0·01,P<0·05),SAP组MMP-9与治疗前比较差异有统计学意义(P<0·05),而TIMP-1无明显改变(P>0·05)。结论ACS患者MMP-9升高及TIMP-1下降,可能与其发病机制相关,普伐他汀能降低ACS患者MMP-9并升高TIMP-1,对于ACS的临床治疗有着重要的意义。
Objective To observe the effect of slmvastatin of serun levels of matrix metalloprotease-9 （MMP-9 ） and tissue inhibitors of matris metalloproteinase-1 （TIMP-1 ） in patients with acute coronary syndromes（ACS）. Methods There were 30 patients with stable angina pectoris（SAP） and 30 patients with ACS. 28 cases of age matched healthy individuals were selected as a control. The serum level of MMP-9 and TIMP-1 were detected by ELISA before and after treatment. Results There was a significant diferencein serum level of MMP-9 and TIMP-1 among SAP group,ACS group and control group. The serum level of MMP-9 and TIMP-1 were diferent between simanastatin treatment before and after 4 weeks treatment. Conclusion ACS may be related to the increased serum level of MMP-9 and the decreased serum level of TIMP-1. Simavastatin can decrease serum level of MMP-9 and in- crease serum level of TIMP-1 ,and it may be have a beneficial effect on clinical treatment.
出处
《中国基层医药》
CAS
2006年第7期1066-1067,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
冠状动脉疾病
普伐他汀
基质金属蛋白酶
组织抑制因子
Coronary disease
Simvastatin
Matris metalloproteinases
Tissue inhibitors of matris metalloproteinase
